Total Valuation
Kaken Pharmaceutical Co has a market cap or net worth of $853.52M. The enterprise value is $103.04B.
Market Cap$853.52M
Enterprise Value$103.04B
Share Statistics
Kaken Pharmaceutical Co has 44,139,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,139,730
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kaken Pharmaceutical Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 9.21%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)9.21%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee84.41M
Profits Per Employee12.52M
Employee Count1,114
Asset Turnover0.49
Inventory Turnover1.88
Valuation Ratios
The current PE Ratio of Kaken Pharmaceutical Co is 67.9. Kaken Pharmaceutical Co’s PEG ratio is -0.87.
PE Ratio67.9
PS Ratio2.04
PB Ratio1.06
Price to Fair Value1.12
Price to FCF-11.15
Price to Operating Cash Flow―
PEG Ratio-0.87
Income Statement
In the last 12 months, Kaken Pharmaceutical Co had revenue of 94.03B and earned 13.95B in profits. Earnings per share was 365.42.
Revenue94.03B
Gross Profit58.26B
Operating Income21.04B
Pretax Income19.43B
Net Income13.95B
EBITDA22.02B
Earnings Per Share (EPS)365.42
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Kaken Pharmaceutical Co pays an annual dividend of $0.587, resulting in a dividend yield of 4.34%
Dividend Per Share$0.587
Dividend Yield4.34%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change-2.40%
50-Day Moving Average25.08
200-Day Moving Average25.19
Relative Strength Index (RSI)45.45
Average Volume (3m)0.00
Important Dates
Kaken Pharmaceutical Co upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Kaken Pharmaceutical Co as a current ratio of 3.67, with Debt / Equity ratio of ―
Current Ratio3.67
Quick Ratio3.04
Debt to Market Cap0.02
Net Debt to EBITDA-2.28
Interest Coverage Ratio751.29
Taxes
In the past 12 months, Kaken Pharmaceutical Co has paid 5.49B in taxes.
Income Tax5.49B
Effective Tax Rate0.28
Enterprise Valuation
Kaken Pharmaceutical Co EV to EBITDA ratio is 5.48, with an EV/FCF ratio of 4.71.
EV to Sales1.28
EV to EBITDA5.48
EV to Free Cash Flow4.71
EV to Operating Cash Flow4.06
Balance Sheet
Kaken Pharmaceutical Co has $70.08B in cash and marketable securities with $3.85B in debt, giving a net cash position of $66.23B billion.
Cash & Marketable Securities$70.08B
Total Debt$3.85B
Net Cash$66.23B
Net Cash Per Share$1.50K
Tangible Book Value Per Share$3.49K
Margins
Gross margin is ―, with operating margin of 22.37%, and net profit margin of 14.83%.
Gross Margin―
Operating Margin22.37%
Pretax Margin20.67%
Net Profit Margin14.83%
EBITDA Margin23.42%
EBIT Margin20.70%
Analyst Forecast
The average price target for Kaken Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-17.50%
EPS Growth Forecast-84.86%